Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States
- This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration in the treatment of TNBC and chemo-resistant lung cancer, alone or in combination with chemotherapy,
radiotherapy or other tumor DNA-damaging agents
- Patent to be granted in the U.S. until 2037
Paris (France), September 3, 2020 – 6 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO), granting the Company a new patent in the United States covering the systemic administration of AsiDNA™ for the treatment of triple negative breast cancer (TNBC) and chemo-resistant lung cancer, alone or in combination with chemotherapy, radiotherapy or other tumor DNA-damaging agents.
The new U.S. patent will add to the robust patent portfolio built around AsiDNA™, the Company’s first-in-class DNA Damage Response (DDR) inhibitor. AsiDNA™ and related compounds, as such and for their various therapeutic uses, are already protected by several patents with a wide scope for the treatment of cancer, alone or in combination with other agents and this new patent is part of Onxeo's aggressive patent strategy, representing a second line of protection in indications and associations of interest.
“Building a strong intellectual property protection around our assets is a key element of our value creation strategy and of course makes sense for AsiDNA™, the most advanced first-in-class asset in our portfolio. This new patent adds a complementary line of protection until 2037 for the use of AsiDNA™ in two indications with high medical need and for which AsiDNA™ in combination with a "DNA-breaker" treatment could represent a major therapeutic response. It is of course in line with our ongoing DRIIV-1b clinical trial associating AsiDNA™ with two chemotherapies, carboplatin and paclitaxel, in tumors eligible for this treatment protocol. This new patent reinforces our confidence in our unique and innovative technology in the field of DNA damage response and contributes to the valuation of this key asset in our portfolio," said Judith Greciet, Chief Executive Officer of Onxeo.